All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your ALL Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The ALL Hub is an independent medical education platform, sponsored by Jazz Pharmaceuticals, Amgen, and Pfizer. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Ponatinib plus chemotherapy and allo-HSCT in newly diagnosed Ph+ ALL: Final results from the PONALFIL trial
Bookmark this article
|
The phase II PONALFIL trial (NCT02776605) from the Programa Español de Tratamientos en Hematología (PETHEMA) group assessed the safety and efficacy of ponatinib in combination with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) with pre-emptive ponatinib after allo-HSCT in 30 adult patients with newly diagnosed (ND) Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).1 The ALL Hub previously reported the initial results from this trial. Below, we summarize the final results from this trial, with a median follow-up of 4 years, presented by Ribera during the European Hematology Association (EHA) 2024 Hybrid Congress.1
|
| Key learnings |
| The complete molecular response rates post-induction (n = 30), post-consolidation (n = 28), and post-allo-HSCT (n = 26) were 47%, 71%, and 100%, respectively. |
| The 4-year overall survival (OS) and event-free survival rates were 92% and 66%, respectively, with no differences according to BCR-ABL1 isoform. |
| Overall, six patients relapsed after the transplant and were successfully managed with ponatinib, chemotherapy, and CAR T-cell therapy or a second allo-HSCT. |
|
A propensity-score comparison between the PONALFIL trial and the PhALL08 trial (NCT01491763), which used imatinib, showed that the PONALFIL cohort had:
|
| These final results from the PONALFIL trial confirm the efficacy of ponatinib in combination with standard induction and consolidation chemotherapy followed by allo-HSCT and further support the use of this regimen as a first-line therapy for adult patients with newly diagnosed Ph+ ALL. |
- Ribera JM. Ponatinib, chemotherapy and transplantation for newly diagnosed adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Final results of the phase 2 PONALFIL trial. Poster #P398. Presented at: European Hematology Association 2024 Hybrid Congress; Jun 13–16, 2024; Madrid, ES.
Your opinion matters
6 votes - 50 days left ...
Related articles
Newsletter
Subscribe to get the best content related to ALL delivered to your inbox